相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Effects of Incretin Hormones on β-Cell Mass and Function, Body Weight, and Hepatic and Myocardial Function
Sunder Mudaliar et al.
AMERICAN JOURNAL OF MEDICINE (2010)
Randomized Controlled Trial Testing the Effects of Weight Loss on Nonalcoholic Steatohepatitis
Kittichai Promrat et al.
HEPATOLOGY (2010)
Glucagon-Like Peptide-1 Receptor Is Present on Human Hepatocytes and Has a Direct Role in Decreasing Hepatic Steatosis In Vitro by Modulating Elements of the Insulin Signaling Pathway
Nitika Arora Gupta et al.
HEPATOLOGY (2010)
Accumulation of Natural Killer T Cells in Progressive Nonalcoholic Fatty Liver Disease
Wing-Kin Syn et al.
HEPATOLOGY (2010)
Liver Enzymes, Nonalcoholic Fatty Liver Disease, and Incident Cardiovascular Disease: A Narrative Review and Clinical Perspective of Prospective Data
Nazim Ghouri et al.
HEPATOLOGY (2010)
PNPLA3 Variants Specifically Confer Increased Risk for Histologic Nonalcoholic Fatty Liver Disease But Not Metabolic Disease
Elizabeth K. Speliotes et al.
HEPATOLOGY (2010)
The Incidence and Risk Factors of Hepatocellular Carcinoma in Patients with Nonalcoholic Steatohepatitis
Mustafa S. Ascha et al.
HEPATOLOGY (2010)
A position statement on NAFLD/NASH based on the EASL 2009 special conference
Vlad Ratziu et al.
JOURNAL OF HEPATOLOGY (2010)
Berberine reduces methylation of the MTTP promoter and alleviates fatty liver induced by a high-fat diet in rats
XinXia Chang et al.
JOURNAL OF LIPID RESEARCH (2010)
Berberine modulates insulin signaling transduction in insulin-resistant cells
Li-Zhong Liu et al.
MOLECULAR AND CELLULAR ENDOCRINOLOGY (2010)
Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial
Frank L. Greenway et al.
LANCET (2010)
Pioglitazone, Vitamin E, or Placebo for Nonalcoholic Steatohepatitis.
Arun J. Sanyal et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Risk of Cardiovascular Disease in Patients with Nonalcoholic Fatty Liver Disease
Giovanni Targher et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Effect of Sibutramine on Cardiovascular Outcomes in Overweight and Obese Subjects
W. Philip T. James et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Berberine improves lipid dysregulation in obesity by controlling central and peripheral AMPK activity
Woo Sik Kim et al.
AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM (2009)
Pioglitazone versus vitamin E versus placebo for the treatment of non-diabetic patients with non-alcoholic steatohepatitis: PIVENS trial design
Naga P. Chalasani et al.
CONTEMPORARY CLINICAL TRIALS (2009)
Cannabinoid receptor antagonists: pharmacological opportunities, clinical experience, and translational prognosis
David R. Janero et al.
EXPERT OPINION ON EMERGING DRUGS (2009)
Hedgehog-Mediated Epithelial-to-Mesenchymal Transition and Fibrogenic Repair in Nonalcoholic Fatty Liver Disease
Wing-Kin Syn et al.
GASTROENTEROLOGY (2009)
VSL#3 Probiotic Treatment Attenuates Fibrosis Without Changes in Steatohepatitis in a Diet-Induced Nonalcoholic Steatohepatitis Model in Mice
Arumugam Velayudham et al.
HEPATOLOGY (2009)
Orlistat for Overweight Subjects with Nonalcoholic Steatohepatitis: A Randomized, Prospective Trial
Stephen A. Harrison et al.
HEPATOLOGY (2009)
A Pilot Study Using Simvastatin in the Treatment of Nonalcoholic Steatohepatitis A Randomized Placebo-controlled Trial
Austin Nelson et al.
JOURNAL OF CLINICAL GASTROENTEROLOGY (2009)
Farnesoid X receptor agonist WAY-362450 attenuates liver inflammation and fibrosis in murine model of non-alcoholic steatohepatitis
Songwen Zhang et al.
JOURNAL OF HEPATOLOGY (2009)
Angiotensin-receptor blockers as therapy for mild-to-moderate hypertension-associated non-alcoholic steatohepatitis
Eugen Florin Georgescu et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2009)
Angiotensin receptor blockers in the treatment of NASH/NAFLD: Could they be a first-class option?
Eugen Florin Georgescu
ADVANCES IN THERAPY (2008)
Carotid artery intima-media thickness in nonalcoholic fatty liver disease
Anna Ludovica Fracanzani et al.
AMERICAN JOURNAL OF MEDICINE (2008)
The farnesoid X receptor (FXR) as a new target in non-alcoholic steatohepatitis
B. Cariou
DIABETES & METABOLISM (2008)
Increased risk of cardiovascular disease in non-alcoholic fatty liver disease: causal effect or epiphenomenon?
G. Targher et al.
DIABETOLOGIA (2008)
Fatigue in non-alcoholic fatty liver disease (NAFLD) is significant and associates with inactivity and excessive daytime sleepiness but not with liver disease severity or insulin resistance
J. L. Newton et al.
GUT (2008)
Role of Leisure-Time Physical Activity in Nonalcoholic Fatty Liver Disease: A Population-Based Study
Shira Zelber-Sagi et al.
HEPATOLOGY (2008)
Statins in liver disease: A molehill, an iceberg, or neither?
Curtis K. Argo et al.
HEPATOLOGY (2008)
Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease
Stefano Romeo et al.
NATURE GENETICS (2008)
Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 years
David C. Klonoff et al.
CURRENT MEDICAL RESEARCH AND OPINION (2008)
Telmisartan, an angiotensin II type 1 receptor blocker, controls progress of nonalcoholic steatohepatitis in rats
Koji Fujita et al.
DIGESTIVE DISEASES AND SCIENCES (2007)
Long term nutritional intake and the risk for non-alcoholic fatty liver disease (NAFLD): A population based study
Shira Zelber-Sagil et al.
JOURNAL OF HEPATOLOGY (2007)
The effects of discontinuing pioglitazone in patients with nonalcoholic steatohepatitis
Glen Lutchman et al.
HEPATOLOGY (2007)
Rosiglitazone evaluated for cardiovascular outcomes - An interim analysis
Philip D. Home et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Rimonabant reduces obesity-associated hepatic steatosis and features of metabolic syndrome in obese Zucker fa/fa rats
Magali Gary-Bobo et al.
HEPATOLOGY (2007)
Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes
Steven E. Nissen et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Glucagon-like peptide-1 gene therapy in obese diabetic mice results in long-term cure of diabetes by improving insulin sensitivity and reducing hepatic gluconeogenesis
Young-Sun Lee et al.
DIABETES (2007)
Inhibition of protein kinase Cε prevents hepatic insulin resistance in nonalcoholic fatty liver disease
Varman T. Samuel et al.
JOURNAL OF CLINICAL INVESTIGATION (2007)
Randomized placebo-controlled trial of ursodeoxycholic acid with vitamin E in nonalcoholic steatohepatitis
Jean-Francois Dufour et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2006)
A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis
Renata Belfort et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes
Daniel J. Drucker et al.
LANCET (2006)
Incretin mimetics as a novel therapeutic option for hepatic steatosis
Maarten E. Tushuizen et al.
LIVER INTERNATIONAL (2006)
Long-term follow-up of patients with NAFLD and elevated liver enzymes
Mattias Ekstedt et al.
HEPATOLOGY (2006)
A pilot study of atorvastatin treatment in dyslipemid, non-alcoholic fatty liver patients
E. Gomez-Dominguez et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2006)
The evolution of severe steatosis after bariatric surgery is related to insulin resistance
Philippe Mathurin et al.
GASTROENTEROLOGY (2006)
Gastric bypass surgery improves metabolic and hepatic abnormalities associated with nonalcoholic fatty liver disease
S Klein et al.
GASTROENTEROLOGY (2006)
NAFLD, obesity, and bariatric surgery
Paul Angulo
GASTROENTEROLOGY (2006)
Nonalcoholic fatty liver disease: From steatosis to cirrhosis
GC Farrell et al.
HEPATOLOGY (2006)
Review article: drug therapy for non-alcoholic fatty liver disease
KM Comar et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2006)
Rosuvastatin as a novel treatment of non-alcoholic fatty liver disease in hyperlipidemic patients
S Antonopoulos et al.
ATHEROSCLEROSIS (2006)
Exendin-4, a glucagon-like protein-1 (GLP-1) receptor agonist, reverses hepatic steatosis in ob/ob mice
XK Ding et al.
HEPATOLOGY (2006)
Effect of changes on body weight and lifestyle in nonalcoholic fatty liver disease
A Suzuki et al.
JOURNAL OF HEPATOLOGY (2005)
Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia
JP Despres et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Randomized trial of lifestyle modification and pharmacotherapy for obesity
TA Wadden et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Beneficial effects of a probiotic VSL#3 on parameters of liver dysfunction in chronic liver diseases
C Loguercio et al.
JOURNAL OF CLINICAL GASTROENTEROLOGY (2005)
A randomized controlled trial of metformin versus vitamin E or prescriptive diet in nonalcoholic fatty liver disease
E Bugianesi et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2005)
One-year intense nutritional counseling results in histological improvement in patients with non-alcoholic steatohepatitis: A pilot study
MA Huang et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2005)
Statins and hepatotoxicity: Focus on patients with fatty liver
N Chalasani
HEPATOLOGY (2005)
Magnetic resonance spectroscopy to measure hepatic triglyceride content: prevalence of hepatic steatosis in the general population
LS Szczepaniak et al.
AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM (2005)
Pravastatin in patients with nonalcoholic steatohepatitis: results of a pilot study
CK Drakoulis et al.
ATHEROSCLEROSIS (2004)
Long term prognosis of fatty liver: risk of chronic liver disease and death
S Dam-Larsen et al.
GUT (2004)
Ursodeoxycholic acid for treatment of nonalcoholic steatohepatitis: Results of a randomized trial
KD Lindor et al.
HEPATOLOGY (2004)
Modest weight loss and physical activity in overweight patients with chronic liver disease results in sustained improvements in alanine aminotransferase, fasting insulin, and quality of life
IJ Hickman et al.
GUT (2004)
A pilot study of orlistat treatment in obese, non-alcoholic steatohepatitis patients
SA Harrison et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2004)
Effects of rosiglitazone and metformin on liver fat content, hepatic insulin resistance, insulin clearance, and gene expression in adipose tissue in patients with type 2 diabetes
M Tiikkainen et al.
DIABETES (2004)
A Pilot Study of Vitamin E Versus Vitamin E and Pioglitazone for the Treatment of Nonalcoholic Steatohepatitis
Arun J. Sanyal et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2004)
Curcumin inhibits NF-κB activation and reduces the severity of experimental steatohepatitis in mice
IA Leclercq et al.
JOURNAL OF HEPATOLOGY (2004)
Vitamin E treatment in pediatric obesity-related liver disease: A randomized study
P Vajro et al.
JOURNAL OF PEDIATRIC GASTROENTEROLOGY AND NUTRITION (2004)
Effects of surgical treatment of the metabolic syndrome on liver fibrosis and cirrhosis
JG Kral et al.
SURGERY (2004)
Therapeutic efficacy of an angiotensin II receptor antagonist in patients with nonalcoholic steatohepatitis
S Yokohama et al.
HEPATOLOGY (2004)
A pilot study of ploglitazone treatment for nonalcoholic steatohepatitis
K Promrat et al.
HEPATOLOGY (2004)
Cytokines and NASH: A pilot study of the effects of lifestyle modification and vitamin E
M Kugelmas et al.
HEPATOLOGY (2003)
A randomized double-blind study of the short-time treatment of obese patients with nonalcoholic fatty liver disease with ursodeoxycholic acid
VN Santos et al.
BRAZILIAN JOURNAL OF MEDICAL AND BIOLOGICAL RESEARCH (2003)
Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome
G Marchesini et al.
HEPATOLOGY (2003)
Probiotics and antibodies to TNF inhibit inflammatory activity and improve nonalcoholic fatty liver disease
ZP Li et al.
HEPATOLOGY (2003)
Fatal liver failure with atorvastatin
L Perger et al.
JOURNAL OF HEPATOLOGY (2003)
Expanding the natural history from cryptogenic cirrhosis to of nonalcoholic steatohepatitis: Hepatocellular carcinoma
E Bugianesi et al.
GASTROENTEROLOGY (2002)
Prevalence of the metabolic syndrome among US adults - Findings from the Third National Health and Nutrition Examination Survey
ES Ford et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2002)
Angiotensin-II type I receptor interaction is a major regulator for liver fibrosis development in rats
H Yoshiji et al.
HEPATOLOGY (2001)
Plasma transforming growth factor-β1 level and efficacy of α-tocopherol in patients with non-alcoholic steatohepatitis:: a pilot study
T Hasegawa et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2001)
Metformin in non-alcoholic steatohepatitis
G Marchesini et al.
LANCET (2001)
Nonalcoholic fatty liver disease: Predictors of nonalcoholic steatohepatitis and liver fibrosis in the severely obese
JB Dixon et al.
GASTROENTEROLOGY (2001)
Betaine for the treatment of nonalcoholic steatohepatitis: A promising new agent.
MF Abdelmalek et al.
GASTROENTEROLOGY (2000)
分享论文
